

DelRicht Achieves First Subject Enrolled in a Phase 3 Pneumococcal Vaccine Trial

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 3 Pneumococcal Vaccine study targeting healthy participants aged 50+ with the most recent vaccination more than one year prior to the start of the trial.

- **Study Enrollment Goal:** 720 patients across 30 sites
- **Patient Population:** Adults 50+ years old
- **Enrollment Period:** February 2026 – March 2026 (1 month)

Our Start-Up Timeline



The Study

Client: Mid-Size Biotech

Trial: U.S. Phase 3 Pneumococcal Vaccine

Participating PIs

Dr. Kymberly Moyer | Hendersonville, TN
Magnolia Family Medicine

Dr. Luke Van Kirk | Springfield, MO
Command Family Medicine

Dr. Patrick Dennis | New Orleans, LA
Touro Medical Center

Key Trial Challenges & Solutions

CHALLENGES

Vaccination Documentation:

Vaccinations frequently occur at retail pharmacies, resulting in significantly **fragmented EMR documentation**.

eDiary Compliance:

Heavy reliance on **eDiary data** for symptom tracking created challenges in ensuring **consistent compliance**, preventing **missed entries**, and **technical support for digital tools for older, unfamiliar populations**.

HOW DELRICHT ADDRESSED

Eligibility Recruitment:

We leveraged our **existing referral networks** and **verified medical records** to rapidly confirm patient eligibility.

Proactive Compliance Monitoring:

We established daily oversight, **real-time reminders** and **automated alerts, 24/7 patient support**, and dedicated coordinators for **immediate follow up** for missed entries, ensuring high data quality.

Our Results

DelRicht's 3 participating sites **enrolled 67 patients** while maintaining a rapid, **same-day average activation to screening timeline**, ultimately achieving **First Subject Enrolled by Dr. Moyer**. In addition to efficient activation and enrollment, our sites maintained a **100% retention rate**. DelRicht demonstrated seamless sponsor/CRO coordination and commitment to patient engagement and retention.

 **Same-Day** Activation to Screening

 **100%** Retention Rate

 **1st** Subject Enrolled (Dr. Moyer)